Ultraviolet Radiation and Its Effects on Plants

Ultraviolet radiation is a portion of the electromagnetic spectrum ranging from 10 to 400 nm, classified into three main categories: UV-A (320–400 nm), UV-B (280–320 nm), and UV-C (100–280 nm). The UV radiation from the sun that crosses the atmosphere and reaches the earth’s surface is composed largely of UV-A radiation (95%) and, to a lesser extent, UV-B (5%), which is normally filtered by stratospheric ozone. With the thinning of the ozone layer, UV-B radiation penetrates deeper into the earth’s surface, where it becomes dangerous due to its high energy content that acts at the molecular level, affecting the cycles of carbon, nitrogen, and other elements, thus, having a direct impact on global warming. On the other hand, UV radiation alters numerous essential organic compounds for living organisms. Since its discovery, it has been established that e UV-B causes alterations in plant development and metabolism, both primary and secondary. In this chapter, we summarize the current knowledge about the effects of UV radiation on the morphological, biochemical, and genetic processes in plants

Educación Superior y Pandemia. Aprendizajes y buenas prácticas en Iberoamérica

La aportación actual no entra en analizar aspectos generales de la pandemia (naturaleza, origen, extensión general y en el país, etc.) o de otras situaciones que se derivan del confinamiento, por considerar que son suficientemente conocidos. Tampoco pretende realizar una recensión de informes sobre la temática elaborados por organismos como la UNESCO-IESALC, el Banco Mundial, el BID o la CRUE y revisar las aportaciones de investigadores de la temática. Más bien trata de aportar concreciones y dimensiones prácticas de la Educación Superior de cada país que puedan ayudar en los aspectos de organización y gestión de estas instituciones. En este sentido considera aspectos referidos a: (1) Desarrollo de las enseñanzas: alteraciones en la duración y estructura de los títulos; modificaciones de objetivos, metodologías y sistemas de evaluación; atención a colectivos vulnerables; etc.(2) Organización institucional: atención a las personas (gestión del alumnado, profesorado y personal de administración y servicios, rol de los directivos, etc.); infraestructuras; desarrollo de procesos (matriculación, gestión administrativa y económica, etc.); y resultados (académicos como tasa de aprobados, nivel de abandono u otros; y no académicos). (3) Vinculación con el entorno: actuaciones de y con la comunidad o colaboraciones significativas. Incluye el escrito de cada país con referencias y reflexiones sobre los anteriores aspectos, así como algunas experiencias de interés y, por último, reflexiones, valoraciones y retos sobre la gestión en los momentos de confinamiento y reapertura, con la idea de identificar aprendizajes significativos y orientaciones de cara a la actuación en la situación actual y similares que se puedan producir en el futuro. Las diferentes aportaciones se centran en la enseñanza universitaria, incluyendo los estudios superiores, que en muchos países tienen gran importancia y desarrollo, y tratan de proporcionar una visión general de los diferentes países sin obviar descender a las particularidades concretas que exigen el identificar buenas prácticas o medidas específicas de organización y desarrollo de la formación. Hablamos del trabajo de 41 especialistas de 13países iberoamericanos que permiten conocer y analizar las actuaciones por países, pero también realizar un estudio de las iniciativas que se han tomado en todos los países considerando algunos de los tópicos que considera el Informe. En todo caso, cabe destacar la actualidad y trascendencia del tema y la rapidez por trasladar a la sociedad un Informe detallado sobre las actuaciones universitarias existentes y sus resultados

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. RESULTS: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m(2), and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. CONCLUSION: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk